Bevacizumab, a recombinant anti-vascular endothelial growth factor antibody, is the antiangiogenic drug used at advanced stage of non-small cell lung cancer. It is the only antiangiogenic therapy up till know available with reimbursement in Hungary. It is indicated in the first-line, platinum-based treatment of advanced stage non-squamous non- small cell lung cancer, and used together with chemotherapy. CASE REPORT- In this case report we present the case of a patient with advanced stage pulmonary adenocarcinoma, with a progression- free survival of more than one year with bevaci- zumab-docetaxel-cisplatine therapy. CONCLUSION - Bevacizumab given together with combination chemotherapy is effective in advanced lung adenocarcinoma.
|Translated title of the contribution||Experience with bevacizumab in non-small cell lung cancer|
|Number of pages||4|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Oct 12 2009|
ASJC Scopus subject areas